ATE169820T1 - Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen - Google Patents

Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen

Info

Publication number
ATE169820T1
ATE169820T1 AT90904068T AT90904068T ATE169820T1 AT E169820 T1 ATE169820 T1 AT E169820T1 AT 90904068 T AT90904068 T AT 90904068T AT 90904068 T AT90904068 T AT 90904068T AT E169820 T1 ATE169820 T1 AT E169820T1
Authority
AT
Austria
Prior art keywords
bactericidal
permeability
endotoxin
treatment
production
Prior art date
Application number
AT90904068T
Other languages
English (en)
Inventor
Marian N Marra
Randal W Scott
Original Assignee
Incyte Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharma Inc filed Critical Incyte Pharma Inc
Application granted granted Critical
Publication of ATE169820T1 publication Critical patent/ATE169820T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
AT90904068T 1989-02-14 1990-02-14 Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen ATE169820T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31084289A 1989-02-14 1989-02-14
US07/468,696 US5089274A (en) 1989-02-14 1990-01-22 Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders

Publications (1)

Publication Number Publication Date
ATE169820T1 true ATE169820T1 (de) 1998-09-15

Family

ID=26977616

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90904068T ATE169820T1 (de) 1989-02-14 1990-02-14 Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen
AT97118279T ATE246933T1 (de) 1989-02-14 1990-02-14 Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur behandlung von mit lipopolysaccharid assoziierten, durch gramnegative bakterien hervorgerufenen infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97118279T ATE246933T1 (de) 1989-02-14 1990-02-14 Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur behandlung von mit lipopolysaccharid assoziierten, durch gramnegative bakterien hervorgerufenen infektionen

Country Status (11)

Country Link
US (1) US5089274A (de)
EP (3) EP1384485A1 (de)
JP (1) JP2966923B2 (de)
KR (1) KR0160133B1 (de)
AT (2) ATE169820T1 (de)
AU (1) AU647734B2 (de)
CA (1) CA2048619C (de)
DE (2) DE69032579T2 (de)
ES (2) ES2205111T3 (de)
IL (1) IL93360A (de)
WO (1) WO1990009183A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6132775A (en) * 1987-08-11 2000-10-17 New York University Therapeutic uses of biologically active bactericidal/permeability-increasing protein fragments
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
EP0375724B1 (de) * 1987-08-11 1995-05-31 New York University Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente
US5594113A (en) * 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US6093801A (en) * 1989-02-14 2000-07-25 Incyte Pharmaceuticals, Inc. Recombinant analogs of bactericidal/permeability increasing protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US5171739A (en) 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
WO1994025476A1 (en) * 1993-04-30 1994-11-10 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
US5489676A (en) * 1990-03-30 1996-02-06 Elsbach; Peter Polypeptides that potentiate bactericidal/permeability-increasing protein and methods for treating bacterial infections
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DE69128968T2 (de) * 1990-12-03 1998-10-08 Univ New York Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
AU2006892A (en) * 1991-05-16 1992-12-30 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
CN1163264C (zh) * 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ES2157981T3 (es) * 1993-03-12 2001-09-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
CA2172245C (en) * 1993-09-22 2003-04-08 Jonathan Cohen Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
ATE219684T1 (de) * 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
DE69526216T2 (de) * 1994-01-14 2002-11-14 Xoma Technology Ltd., Berkeley Antifungaleverfahren und mitteln
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
WO1995028949A1 (en) * 1994-04-21 1995-11-02 Novo Nordisk A/S Heparin-binding protein for the treatment of sepsis and processes for its preparation
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US5610075A (en) * 1995-01-17 1997-03-11 Stahl-Rees; Marianne Competitive electrochemiluminescence assays for endotoxins using a ruthenium label
US5939390A (en) * 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
NZ332720A (en) * 1996-05-10 2000-07-28 Xoma Corp Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
CN1155403C (zh) * 1996-05-23 2004-06-30 爱克索马技术有限公司 杀细菌／通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用
JP2000511892A (ja) * 1996-05-24 2000-09-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 可溶性ベーターシート形成性ペプチドの合成
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
AU768075B2 (en) * 1998-10-22 2003-12-04 Eli Lilly And Company Methods for treating sepsis
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CA3022426C (en) 2016-05-27 2023-05-16 Exoxemis, Inc. Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006279A1 (en) * 1985-04-30 1986-11-06 Scripps Clinic And Research Foundation Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods
EP0487517A1 (de) * 1986-10-07 1992-06-03 Mainframe Data Limited Vorrichtung und verfahren zum überwachen der übertragung von gebrechen
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
EP0375724B1 (de) * 1987-08-11 1995-05-31 New York University Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente
GB8815978D0 (en) * 1988-07-05 1988-08-10 British Telecomm Method & apparatus for encoding decoding & transmitting data in compressed form

Also Published As

Publication number Publication date
IL93360A (en) 1997-04-15
EP0460058A4 (en) 1992-02-12
DE69034096T2 (de) 2004-06-17
CA2048619C (en) 2001-02-13
JP2966923B2 (ja) 1999-10-25
DE69032579D1 (de) 1998-09-24
KR0160133B1 (en) 1998-12-01
DE69032579T2 (de) 1999-02-11
US5089274A (en) 1992-02-18
ATE246933T1 (de) 2003-08-15
JPH04506510A (ja) 1992-11-12
DE69034096D1 (de) 2003-09-18
AU5170690A (en) 1990-09-05
WO1990009183A1 (en) 1990-08-23
EP0841064B1 (de) 2003-08-13
EP0460058A1 (de) 1991-12-11
EP1384485A1 (de) 2004-01-28
ES2122958T3 (es) 1999-01-01
AU647734B2 (en) 1994-03-31
CA2048619A1 (en) 1990-08-15
ES2205111T3 (es) 2004-05-01
EP0460058B1 (de) 1998-08-19
EP0841064A1 (de) 1998-05-13

Similar Documents

Publication Publication Date Title
ATE169820T1 (de) Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE3855525D1 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE3577650D1 (de) Vorrichtung zur dehnung von koerpergewebe.
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
ATE184193T1 (de) Verwendung von n-acylaminoalkoholen zur herstellung eines arzneimittels zur behandlung von mastzellerkrankungen
DE3484055D1 (de) Verwendung von ubidecarenon zur herstellung eines medikaments zur behandlung von durch radiotherapie hervorgerufenen geschwueren.
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DE3681144D1 (de) Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren.
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
FR2607517B2 (fr) Vecteurs d'expression de variants de l'hirudine dans les levures, procede et produit obtenu
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
ATE154608T1 (de) Verwendung einer mischung von peptiden and aminosäuren für die prophylaxis oder behandlung von dementia
DE3674213D1 (de) Verfahren zur herstellung von keimabgetoeteten oder in ihrer virulenz abgeschwaechten substanzen sowie deren verwendung.
DE69804850D1 (de) Verfahren zur herstellung eines kappa-casein-glykomakropeptides oder eines abkoemmlings davon
DE3884324D1 (de) Verfahren zur Herstellung von menschlichen pro-apolipoprotein-A-I-ähnlichen Proteinen.
DE68922150D1 (de) Vorrichtung zur elektrochemischen Behandlung.
DE58908855D1 (de) Verfahren zur Herstellung von Gate-Elektroden.
DE3884261D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten.
DE3485773D1 (de) Aus kultivierten mesenchymzellen extrahierte makromolekuele zur behandlung von degenerationskrankheiten.
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties